Radiation therapy is commonlyused for the treatment of lung cancer. However, radiation pneumonitis frequently occurs as a complication of the radiation therapy. Although corticosteroids are widely used for the treatment of radiation pneumonitis, they are not always effective. In this report, we used cycosporin A in the treatment of a patient suffering from steroid-refractory radiation pneumonitis. To our knowledge, this is the first report in which cyclosporin A was successfully used in the treatment of radiation pneumonitis. (Internal Medicine 41: 730-733, 2002) 
Introduction
Radiotherapy is commonlyused for the treatment of intrathoracic neoplastic diseases. It has been reported that radiation pneumonitis occurs in approximately 5 to 15%of patients who have received radiation therapy for lung cancer (1 , 2) . It is usually recognized between 2 to 6 months from the end of radiotherapy (3) . Clinical symptoms are characterized by the developmentof cough, shortness of breath, and fever. Arterial blood gases often showhypoxemiaand an increased alveolar-arterial gradient of oxygen. Of all diagnostic tests, the chest radiograph is undoubtedly the most crucial test. The hallmark of radiation pneumonitis is the straight, sharp edge of the infiltrate, corresponding to the boundary of the irradiated areas (3, 4) . No definite therapy has been established to improve radiation pneumonitis. In severe cases, however, most clinicians agree with steroid usage (3).
Currently, immunosuppressive agents are used in somepatients whodo not respond to corticosteroids. Since an immunologically mediated mechanism is suggested by many investigators as the cause of radiation pneumonitis, the combination of a corticosteroid and immunosuppressive agents may be effective in patients with severe radiation pneumonitis (5) . In this paper, we report a patient with steroid-refractory radiation pneumonotis whowas successfully treated with cyclosporin A.
Case Report
A 76-year-old manwas admitted to our hospital in June 2001. He had a medical history of smoking. One month prior to hospitalization, he had experienced hemosputum and right chest pain. Physical and laboratory examinations disclosed no abnormalities. Arterial blood gases while breathing room air showed an arterial oxygen tension of 77 mmHgand arterial carbon dioxide tension of 37 mmHg. Lung function studies showed a vital capacity of 86.8% and forced expiratory volume in Is was (FEV1) 57.8%. Chest radiograph and a computed tomography (CT) scan of the thorax revealed a 4x2x2-cm mass in the right hilar area with right hilar lymphadenopathy (Fig. 1A, B) . Fiberoptic bronchoscopy showed an extrabronchial compression of the right B3 and cytologic findings were positive for small cell carcinoma. The staging of lung carcinoma was consistent with a limited disease (stage T2N1M0). The patient was treated with carboplatin, doxorubicin, and etoposide with concomitant radiotherapy. Four cycles of chemotherapy with the same agents were given. The patient received a total of 55.2 gray (Gy) radiation using 10-MV Xray to a field encompassing the primary tumor with a 12x11-cm field size. Radiotherapy was given over 5 weeks. Finally, he achieved clinical complete response (CR). Twomonths after completion of radiotherapy, the patient developed a non productive cough, high-grade fever, and arterial blood gases examined while breathing room air showed an arterial oxygen tension of 65 mmHgand arterial carbon dioxide tension of 32 mmHg. The chest radiograph revealed shaggy infiltrates, corresponding to the previous irradiated areas ( monitis. He was treated with 500 mgof methylprednisolone drip per day for three days, and the symptoms and pulmonary infiltrates resolved gradually. During the period maintenance prednisolone at the dosage of 60 mg per day was beneficial, but decreasing to a dose of 30 mg per day led to increased symptomsand worsening of the chest radiograph. Since "rebound" pneumonitis following the withdrawal of steroid therapy was suspected, steroid pulse therapy was reinstituted. However, there wasno apparent clinical or radiological improve- During the treatments, wesuccessively measured his serum CRP,surfactant protein A(SP-A),surfactant protein D(SP-D) andInterleukin-6 (IL-6)levelsas markers of theactivityof radiationpneumonitis (6, 7) . In this patient,thesemarkersincreasedevenafter steroidpulsetherapy,compared withthe baselinelevelsbeforeradiotherapy.However, theydecreased remarkably after the CsAadministration (Fig. 3) .
Discussion
Explanations for radiationpneumonitis havefocusedondirect damage to typeII pneumocytes andendothelial cells leadingtothereleaseof a "cascade of cytokines" including growth factors(8-10).In turn, growth factorreceptorsonfibroblasts maybeactivatedandresultin collagenproduction andfibrosis. Another proposed mechanism of lunginjuryattributableto irradiationpostulatesthatradiationtreatment resultsin increasing alveolar-capillarypermeabilityand,in turn, leadsto decreasedalveolarstability andloss of airspaceprotection (1 1). Otherinvestigatorshavesuggestedthat lunginjuryresults from theproduction offreeradicalsthatcouldcause damage tostructural macromolecules andleaky cell membranes (12, 13) . The aforementioned mechanisms presume the directdamage to lung tissues causedbyirradiation.Noneofthesetheories,however, canadequately account for theoccurrence ofinjuryoutside the field of irradiation. Currently,an immunologically mediated mechanism seems to bemostplausible.Onesuggestion hasbeenthat the initial localradiation damage may causethereleaseofautoantigens that are recognized byactivatedpulmonary lymphocytes. The actionof theselymphocytes leadsto the development ofa diffuse bilateral lymphocytic alveolitis (14, 15) . In addition, Gibsonet al reportedthat animmunologically mediated mechanismsuchas hypersensitivity pneumonitis mayexplaintheinjury both in irradiated and unirradiated lung (16) . Theyperformed bronchoalveolar lavageandfoundintensealveolarlymphocytosisnot onlyin theirradiatedlungbut alsoin thecontralateral lung.Thisfindingsuggeststhat radiotherapycauses immunologically mediatedmechanisms. In fact, McCarty et al reported thesuccessful useofazathioprine as animmunosuppressive agentin a patientwithsevereradiationpneumonitis (5) . Under this immunological background, weusedCsA in a patientwithsteroid-refractory radiationpneumonitis.
CsA is a well-established immunosuppressant thatactson CD4+T cells byblockingtranscription of the interleukin-2 gene.Thisagenthasbeenappliedto patientswithautoimmune connective tissuedisease in addition to organtransplantation (17) (18) (19) (20) . Theefficacyof this agentforseveraldiseasescombinedwithinterstitial pneumonitis is recognized. CsAreduces thehumoral andcellularimmune response andmayhavea role in the treatment of cryptogenic fibrosing alveolitis (21) . In contrast to other immunosuppressiveagents, such as azathioprine, CsA appears to be free from myelotoxicity and does not impair the level or proliferative capacity of hematopoietic stem cells (22) . In addition, CsA is a fairly safe drug, because no rebound phenomenon is observed after discontinuation, and the frequency of side effects seems to be low if the serum concentration is monitored carefully (17) . Elderly patients with steroid-dependent radiation pneumonitiscan havesevere side effects including immunesuppression, weight gain, osteoporosis, and endocrine dysfunction. Therefore, we treated our patient with CsA, and succeeded in improving his lung involvement and symptomswithout any complications due to corticosteroids.
The fundamental question in the present case is whether CsA affects the growth of residual carcinoma or not. Because we knowthat immunosuppressivetherapy has the potential for increasing the incidence of certain malignancies. Hojo et al reported that CsAcan promote cancer progression by a direct cellular effect that is independent of its effect on the host's immune cells, and that cyclosporine-induced TGF-(3 production is involved in this mechanism (23) . Several conflicting data are presented in this field, however, the bulk of the evidence suggests that immunosuppression favors the growth of existing cancer cells (24) . Therefore, the administration of CsA should be limited to patients whosuffer from uncontrollable radiation pneumonitis with corticosteroids. In addition, CsA should not be used for a long period after improvement of the radiation pneumonitis.
In conclusion, CsAis worthy of being applied for progressed radiation pneumonitis. It offers a safe, well-tolerated option in the treatment of patients with radiation pneumonitis. Additional patients at our institution will be treated with CsAcombined with corticosteroids to further elucidate its role in the management of severe radiation pneumonitis.
